Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel DOK2 docking protein 2
  • Tie2 Signaling
  • RET signaling
Novel DOK4 docking protein 4
  • RET signaling
Novel DPYD dihydropyrimidine dehydrogenase
  • Pyrimidine catabolism
  • (5S)-5-Iododihydro-2,4(1H,3H)-pyrimidinedione
  • NADPH
  • 6-Carboxymethyluracil
  • Flavin adenine dinucleotide
  • Flavin mononucleotide
  • Uracil
  • Eniluracil
  • 5-Iodouracil
  • Gimeracil
  • Tegafur-uracil
  • Dihydropyrimidine dehydrogenase deficiency
Novel DUSP12 dual specificity phosphatase 12
Novel EFNA5 ephrin A5
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
Novel EFNB1 ephrin B1
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
Novel EFNB2 ephrin B2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
Novel EFS embryonal Fyn-associated substrate
Novel EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
Novel EGLN1 egl-9 family hypoxia inducible factor 1
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Ascorbic acid
  • Iron
  • Roxadustat
  • N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINE
  • FG-2216
  • Daprodustat
  • Vadadustat
  • Ferrous gluconate
  • Ferrous succinate
  • Ferrous ascorbate
  • Ferrous fumarate
  • Ferrous glycine sulfate
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
Novel EMD emerin
  • Nuclear Envelope Breakdown
  • Initiation of Nuclear Envelope (NE) Reformation
  • Depolymerization of the Nuclear Lamina
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOG GTPase cycle
  • RAC3 GTPase cycle
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Emery-Dreifuss muscular dystrophy
Novel ENO1 enolase 1
  • Glycolysis
  • Gluconeogenesis
  • Manipulation of host energy metabolism
  • Zinc
  • Copper
  • Artenimol
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Novel ENPP7 ectonucleotide pyrophosphatase/phosphodiesterase 7
  • Glycosphingolipid catabolism
Novel EPHA3 EPH receptor A3
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib
Novel EPHA4 EPH receptor A4
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Somitogenesis
  • Fostamatinib
Novel EPHB2 EPH receptor B2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • L1CAM interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Fostamatinib
  • Oleandrin
Novel EPS8 EGFR pathway substrate 8, signaling adaptor
  • Sensory processing of sound by inner hair cells of the cochlea
  • Sensory processing of sound by outer hair cells of the cochlea
Novel ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Breast cancer
  • Cervical cancer
  • Cholangiocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Ovarian cancer
  • Choriocarcinoma
  • Endometrial Cancer
  • Bladder cancer
Novel ERBB3 erb-b2 receptor tyrosine kinase 3
  • Tucatinib
  • Type I diabetes mellitus
  • Lethal congenital contractural syndrome (LCCS)
Novel ERBB4 erb-b2 receptor tyrosine kinase 4
  • Afatinib
  • Fostamatinib
  • Brigatinib
  • Zanubrutinib

Page 5 out of 32 pages